Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)

This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.

Trial Details

NCT ID
NCT05833724
Phase
PHASE2
Sponsor
Great Novel Therapeutics Biotech & Medicals Corporation
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Chidamide
Locations (sample)
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • Kaohsiung City, Taiwan|22.61626,120.31333
  • New Taipei City, Taiwan|25.06199,121.45703
  • Taichung, Taiwan|24.1469,120.6839
  • Taipei, Taiwan|25.05306,121.52639

Key Eligibility Criteria

  • Histopathological diagnosis, made by the investigator, of the following PTCL subtypes as defined by the WHO classification (2016) may be included: …
  • Patients for whom at least one measurable lesion according to Cheson Criteria 2014 at baseline.
  • Relapsed or refractory disease (including DOR shorter than 30 days) to ≥1 prior systemic therapy including, but not limited to, chemotherapy, targe…
  • Male or female, aged 20-75 years (inclusive).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →